Last checked at 
Feedback PLC - London-based medical imaging technology company - Says Bleepa medical imaging platform has been given a UKCA mark, which offers post-Brexit UK regulatory certification. Feedback says Bleepa is it's "core product". Bleepa is an app that allows front-line clinicians and medical teams to assess imaging results and patient decisions remotely and securely. Earlier this month, Bleepa was made available on the Apple App Store and Google Play.
Chief Executive Tom Oakley notes: "In addition to the CE mark affixed last year, Bleepa has now enhanced its regulatory technical file to include the UK's medical Device Manufacturing mark. The new UK product marking is used for goods being placed on the market in Great Britain post-Brexit and further validates as well as provides confidence in the quality and expertise of Bleepa's technology."
Current stock price: 1.00 pence, up 5.3% on Tuesday morning
Year-to-date change: down 7.4%
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.